vs

Side-by-side financial comparison of NEOGENOMICS INC (NEO) and CPI Card Group Inc. (PMTS). Click either name above to swap in a different company.

NEOGENOMICS INC is the larger business by last-quarter revenue ($186.7M vs $153.1M, roughly 1.2× CPI Card Group Inc.). CPI Card Group Inc. runs the higher net margin — 4.8% vs -57.9%, a 62.7% gap on every dollar of revenue. On growth, CPI Card Group Inc. posted the faster year-over-year revenue change (22.3% vs 11.1%). Over the past eight quarters, CPI Card Group Inc.'s revenue compounded faster (16.9% CAGR vs 6.5%).

NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is an American CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics.

CPI Card Group Inc. is a leading provider of payment card production and associated solutions, including contactless and contact credit/debit cards, prepaid cards, and card personalization services. It primarily serves financial institutions, fintech firms, and retail brands across its core North American market.

NEO vs PMTS — Head-to-Head

Bigger by revenue
NEO
NEO
1.2× larger
NEO
$186.7M
$153.1M
PMTS
Growing faster (revenue YoY)
PMTS
PMTS
+11.3% gap
PMTS
22.3%
11.1%
NEO
Higher net margin
PMTS
PMTS
62.7% more per $
PMTS
4.8%
-57.9%
NEO
Faster 2-yr revenue CAGR
PMTS
PMTS
Annualised
PMTS
16.9%
6.5%
NEO

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
NEO
NEO
PMTS
PMTS
Revenue
$186.7M
$153.1M
Net Profit
$-108.0M
$7.3M
Gross Margin
43.3%
31.5%
Operating Margin
46.9%
12.0%
Net Margin
-57.9%
4.8%
Revenue YoY
11.1%
22.3%
Net Profit YoY
42.0%
8.5%
EPS (diluted)
$-0.13
$0.62

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NEO
NEO
PMTS
PMTS
Q1 26
$186.7M
Q4 25
$190.2M
$153.1M
Q3 25
$187.8M
$138.0M
Q2 25
$181.3M
$129.8M
Q1 25
$168.0M
$122.8M
Q4 24
$172.0M
$125.1M
Q3 24
$167.8M
$124.8M
Q2 24
$164.5M
$118.8M
Net Profit
NEO
NEO
PMTS
PMTS
Q1 26
$-108.0M
Q4 25
$7.3M
Q3 25
$-27.1M
$2.3M
Q2 25
$-45.1M
$518.0K
Q1 25
$-25.9M
$4.8M
Q4 24
$6.8M
Q3 24
$-17.7M
$1.3M
Q2 24
$-18.6M
$6.0M
Gross Margin
NEO
NEO
PMTS
PMTS
Q1 26
43.3%
Q4 25
43.8%
31.5%
Q3 25
42.8%
29.7%
Q2 25
42.6%
30.9%
Q1 25
43.6%
33.2%
Q4 24
44.9%
34.1%
Q3 24
44.6%
35.8%
Q2 24
44.1%
35.7%
Operating Margin
NEO
NEO
PMTS
PMTS
Q1 26
46.9%
Q4 25
-7.1%
12.0%
Q3 25
-14.4%
9.4%
Q2 25
-26.3%
7.3%
Q1 25
-16.6%
11.5%
Q4 24
-10.7%
12.7%
Q3 24
-12.6%
14.3%
Q2 24
-13.3%
12.5%
Net Margin
NEO
NEO
PMTS
PMTS
Q1 26
-57.9%
Q4 25
4.8%
Q3 25
-14.4%
1.7%
Q2 25
-24.9%
0.4%
Q1 25
-15.4%
3.9%
Q4 24
5.4%
Q3 24
-10.5%
1.0%
Q2 24
-11.3%
5.1%
EPS (diluted)
NEO
NEO
PMTS
PMTS
Q1 26
$-0.13
Q4 25
$0.62
Q3 25
$0.19
Q2 25
$0.04
Q1 25
$0.40
Q4 24
$0.56
Q3 24
$0.11
Q2 24
$0.51

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NEO
NEO
PMTS
PMTS
Cash + ST InvestmentsLiquidity on hand
$146.1M
$21.7M
Total DebtLower is stronger
$286.7M
Stockholders' EquityBook value
$828.8M
$-17.3M
Total Assets
$1.3B
$403.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NEO
NEO
PMTS
PMTS
Q1 26
$146.1M
Q4 25
$159.6M
$21.7M
Q3 25
$164.1M
$16.0M
Q2 25
$154.7M
$17.1M
Q1 25
$346.2M
$31.5M
Q4 24
$367.0M
$33.5M
Q3 24
$362.0M
$14.7M
Q2 24
$355.1M
$7.5M
Total Debt
NEO
NEO
PMTS
PMTS
Q1 26
Q4 25
$341.9M
$286.7M
Q3 25
$308.4M
Q2 25
$310.9M
Q1 25
$280.7M
Q4 24
$541.1M
$280.4M
Q3 24
$280.2M
Q2 24
$269.7M
Stockholders' Equity
NEO
NEO
PMTS
PMTS
Q1 26
$828.8M
Q4 25
$836.6M
$-17.3M
Q3 25
$838.3M
$-25.7M
Q2 25
$854.0M
$-29.0M
Q1 25
$888.3M
$-29.7M
Q4 24
$902.3M
$-35.6M
Q3 24
$908.2M
$-42.8M
Q2 24
$915.9M
$-44.6M
Total Assets
NEO
NEO
PMTS
PMTS
Q1 26
$1.3B
Q4 25
$1.4B
$403.2M
Q3 25
$1.4B
$407.1M
Q2 25
$1.4B
$399.8M
Q1 25
$1.6B
$351.9M
Q4 24
$1.6B
$349.7M
Q3 24
$1.6B
$342.3M
Q2 24
$1.6B
$321.4M
Debt / Equity
NEO
NEO
PMTS
PMTS
Q1 26
Q4 25
0.41×
Q3 25
Q2 25
Q1 25
Q4 24
0.60×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NEO
NEO
PMTS
PMTS
Operating Cash FlowLast quarter
$-8.1M
$39.6M
Free Cash FlowOCF − Capex
$35.2M
FCF MarginFCF / Revenue
23.0%
Capex IntensityCapex / Revenue
2.9%
Cash ConversionOCF / Net Profit
5.39×
TTM Free Cash FlowTrailing 4 quarters
$41.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NEO
NEO
PMTS
PMTS
Q1 26
$-8.1M
Q4 25
$1.3M
$39.6M
Q3 25
$8.9M
$10.0M
Q2 25
$20.3M
$4.3M
Q1 25
$-25.3M
$5.6M
Q4 24
$9.8M
$26.7M
Q3 24
$9.2M
$12.5M
Q2 24
$13.9M
$-4.8M
Free Cash Flow
NEO
NEO
PMTS
PMTS
Q1 26
Q4 25
$-6.5M
$35.2M
Q3 25
$570.0K
$5.3M
Q2 25
$14.0M
$533.0K
Q1 25
$-29.8M
$292.0K
Q4 24
$-1.8M
$21.6M
Q3 24
$-1.6M
$11.1M
Q2 24
$814.0K
$-6.0M
FCF Margin
NEO
NEO
PMTS
PMTS
Q1 26
Q4 25
-3.4%
23.0%
Q3 25
0.3%
3.8%
Q2 25
7.7%
0.4%
Q1 25
-17.8%
0.2%
Q4 24
-1.0%
17.3%
Q3 24
-0.9%
8.9%
Q2 24
0.5%
-5.0%
Capex Intensity
NEO
NEO
PMTS
PMTS
Q1 26
Q4 25
4.1%
2.9%
Q3 25
4.4%
3.4%
Q2 25
3.5%
2.9%
Q1 25
2.7%
4.3%
Q4 24
6.7%
4.0%
Q3 24
6.4%
1.2%
Q2 24
8.0%
1.0%
Cash Conversion
NEO
NEO
PMTS
PMTS
Q1 26
Q4 25
5.39×
Q3 25
4.32×
Q2 25
8.39×
Q1 25
1.17×
Q4 24
3.94×
Q3 24
9.70×
Q2 24
-0.79×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NEO
NEO

Segment breakdown not available.

PMTS
PMTS

US Debit And Credit$128.9M84%
US Prepaid Debit$24.4M16%

Related Comparisons